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Abstract
Background: Loss of parvalbumin interneurons in the hippocampus is a robust finding in schizophrenia brains. Rats exposed 
during embryonic day 17 to methylazoxymethanol acetate exhibit characteristics consistent with an animal model of 
schizophrenia, including decreased parvalbumin interneurons in the ventral hippocampus. We reported previously that 
peripubertal administration of diazepam prevented the emergence of pathophysiology in adult methylazoxymethanol 
acetate rats.
Methods: We used an unbiased stereological method to examine the impact of peripubertal diazepam treatment on 
parvalbumin interneuron number in the ventral subiculum, dentate gyrus of the hippocampus and the basolateral amygdala.
Results: Methylazoxymethanol acetate rats with peripubertal diazepam showed significantly more parvalbumin interneurons 
(3355 ± 173 in the ventral subiculum, 1211 ± 76 in the dentate gyrus) than methylazoxymethanol acetate without diazepam 
(2375 ± 109 and 824 ± 54, respectively). No change was found in the basolateral amygdala.
Conclusions: Peripubertal diazepam attenuated the decrease of parvalbumin in the ventral hippocampus of methylazoxymethanol 
acetate rats.
Keywords: schizophrenia, animal model, diazepam, parvalbumin interneuron
Introduction
Loss of parvalbumin interneurons is one of the most robust find-
ings from postmortem brains of schizophrenia patients (Volk 
and Lewis, 2002; Zhang and Reynolds, 2002; Konradi et al., 2011; 
Wang et al., 2011). These fast-spiking, parvalbumin-expressing 
interneurons are required for gamma oscillations (Sohal et al., 
2009) and impact multiple cognitive functions, both of which 
are disrupted in schizophrenia patients (Uhlhaas and Singer, 
2015). Loss of parvalbumin interneurons in the hippocam-
pus and prefrontal cortex has been reported in many animal 
models of schizophrenia, including neonatal hippocampal 
lesion (Cabungcal et  al., 2014), maternal immune activation 
(Piontkewitz et al., 2012), amygdala disinhibition (Berretta et al., 
2009), and MAM-E17 models (Penschuck et al., 2006; Lodge et al., 
2009; Chen et al., 2014; Gill and Grace, 2014).
Rats exposed during embryonic day 17 (E17) to a mitotoxin, 
methylazoxymethanol acetate (MAM), exhibit behavioral, phar-
macological, and anatomical characteristics consistent with 
an animal model of schizophrenia (Lodge and Grace, 2009). 
These rats exhibit increases in dopamine neuron population 
activity, which are thought to underlie the enhanced locomotor 
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response to amphetamine and other psychostimulants (Moore et 
al., 2006) and are driven by pathologically excessive activity of the 
hippocampus (Lodge and Grace, 2007). Hippocampal hyperactivity 
in turn correlates with decreased density of parvalbumin interneu-
rons (Lodge et al., 2009). This loss of parvalbumin interneurons in 
the hippocampus of MAM rats begins while juveniles and persists 
into adulthood (Chen et al., 2014; Gill and Grace, 2014).
Peripubertal administration of diazepam (PD31-40) prevents 
the emergence of the hyperdopaminergic state in adult MAM rats 
by alleviating the heightened level of anxiety during the peripu-
bertal period (Du and Grace, 2013). However, the cellular mecha-
nism by which this protection occurs is unclear. Parvalbumin 
interneurons, especially those in the hippocampus, are sensitive 
to chronic stress (Czeh et al., 2015; Hu et al., 2010). Therefore, one 
possibility is that this treatment to alleviate stress could protect 
parvalbumin interneurons from further loss. In this study, we 
investigated whether peripubertal administration of diazepam 
can prevent the loss of parvalbumin interneurons in MAM rats.
In addition to alterations in the hippocampus, hyperactivity 
of the basolateral amygdala (BLA) was observed in both peripu-
bertal and adult MAM rats (Du and Grace, 2016). The BLA also 
contains a high density of parvalbumin interneurons, innervat-
ing and regulating the firing of projection neurons. Therefore, we 
also examined whether a reduction in parvalbumin interneu-
rons in the BLA contributed to its hyperactivity.
Methods
Animals
All procedures were conducted in accordance with the Guide 
for the Care and Use of Laboratory Animals by the United 
States Public Health Service and approved by the University 
of Pittsburgh Institutional Animal Care and Use Committee. 
Pregnant Sprague-Dawley dams were obtained from Harlan on 
gestational day (GD) 15 and administered MAM (20 mg/kg, i.p., 
Midwest Research Institute, Kansas City, MO) or saline (Sal) on 
GD 17. Litters were weaned on postnatal day 23 and housed 2 to 
3/cage. Only male offspring were used. Animals were housed in 
a normal light cycle (lights on 7 am to 7 pm).
Oral Administration of Diazepam
Diazepam (2-mg tablets, Watson Laboratories, Inc., Corona, 
CA) was ground to powder and mixed with sweetened con-
densed milk (Eagle Brand), sucrose powder, and ground mini 
Nilla Wafers (Kraft Food). Diazepam mixture (5 mg/kg) or the 
same mixture without diazepam was administered during the 
peripubertal period with once-daily administration on 10 con-
secutive days (PD31-40), as described previously (Du and Grace, 
2013, 2016). The oral administration route was chosen because 
it is less stressful than i.p. injections, especially for rats at the 
peripubertal age that are more sensitive to stress, as well as 
better mimicking the preferred route of drug administration to 
patients.
Tissue Preparation
Adult rats (PD83) were anesthetized with sodium pentobarbital 
(60 mg/kg, i.p.) and perfused transcardially with saline followed 
by 4% paraformaldehyde in 0.1 M phosphate buffer (PB). Brains 
were removed, fixed in 4 % paraformaldehyde for 30 minutes, 
and stored in 0.1 M PB. Before slicing, sections were cryopro-
tected in 25% sucrose in 0.1 M PB for 48 hours and sliced into 
60-μm coronal sections. Every fourth section throughout the 
BLA, ventral subiculum (vSub), and dentate gyrus (DG) of the 
hippocampus was used for immunohistochemistry, as a ran-
dom series. Adjacent sections were used for Cresyl violet stain-
ing. A total of 9 to 11 sections for Sal:Veh, 8 to 10 for Sal:DZ, 8 to 9 
for MAM:Veh, and 9 to 10 for MAM:DZ were used throughout the 
vSub; 6 sections for Sal:veh and Sal:DZ and 5 to 6 for MAM:Veh 
and MAM:DZ were from DG. A total of 12 to 14 sections for Sal 
and 13 to 16 for MAM were from the BLA.
Immunohistochemistry
Free-floating sections were rinsed in 0.01M PBS and treated 
with 0.5% sodium borohydride for 30 minutes and 1% hydro-
gen peroxide. Sections were blocked for 1 hour with 3% normal 
goat serum and 0.5% Triton in 0.01 M PBS and incubated with 
primary antibody (rabbit polyclonal anti-parvalbumin, 1:5000, 
PV27, Swant) in the same blocking solution overnight at room 
temperature. Sections were then incubated in biotinylated sec-
ondary antibody (goat anti-rabbit, 1:500, Vector) for 1 hour and 
then in VECTASTAIN Standard ABC Kit for 40 minutes. Following 
TBS rinses, the immunoperoxidase reaction was performed in 
3’3’-diaminobenzidene solution containing 0.1% hydrogen per-
oxide for 5 minutes. Sections were mounted on gelatin-coated 
glass slides; dehydrated through 50%, 75%, 95%, and 100% alco-
hol and xylene; and coverslipped with permount.
Stereology
Parvalbumin positive cells were counted in the right BLA, vSub, 
and DG using an unbiased stereological method: optical frac-
tionator (West et al., 1991). The optical fractionator method pro-
vides unbiased estimates of neuron numbers, which are free of 
assumptions about neuron size and shape.
Sections were examined using a Nikon microscope with a 
motorized stage (Ludl Electronic Products, Hawthorne, NY) and 
a digital camera (QImage), using StereoInvestigator 9 software 
(MicroBrightfield, Inc., Williston, VT). Researchers were blind to 
treatment of animals. Boundaries of regions of interest were 
traced on cresyl violet-stained sections, modified on peroxi-
dase-stained sections under 2.5× objective lens, and refined 
under 10×. Counting was performed using a 60× objective. For 
the BLA, a 200-μm * 200-μm counting frame was used in a grid 
size of 325 μm * 325 μm; for vSub, a 150-μm * 150-μm counting 
frame was used in a grid size of 300 μm * 300 μm; and for ventral 
DG, a 250-μm * 250-μm counting frame was used in a grid size of 
300 μm * 300 μm. A 12-μm height was chosen for counting, with 
3 μm for the top guard zone and the rest as bottom guard zone. 
The coefficient of error Gundersen (m = 0), which describes the 
accuracy of the optical fractionator method used, ranged from 
0.07 to 0.17 (average 0.10) for vSub quantification, 0.09 to 0.18 
(average 0.12) for ventral DG, 0.07 to 0.12 (average 0.08) for BLA.
The BLA comprises the lateral, basolateral, and the basomedial 
nuclei. Boundaries of the BLA were defined according to an atlas of 
the rat brain (Paxinos and Watson, 1986) and previous studies. The 
upper and medial border, for the anterior portion of the BLA, was 
determined by the different cytoarchitecture of the BLA, which 
contrasted with the caudate-putamen and central nucleus of the 
amygdala; the posterior portion of BLA is adjacent to lateral ven-
tricle. Laterally the BLA is bordered by the external capsule.
For vSub, only the pyramidal cell layers, where most parval-
bumin interneurons were located, were counted. The division 
between vSub and CA1 subregions of the hippocampus was 
defined by an abrupt widening of the pyramidal layer. And the 
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border between the vSub and presubiculum cortex was defined 
by the sharp transition to the smaller cells of the presubiculum. 
The borders of the hilus of the ventral DG were defined by the 
inner edge of the granule cell layer of DG, and pyramidal and 
molecular cell layers of CA3 (West et al., 1991).
Data Analysis and Statistics
Estimates of neuron population were determined by the soft-
ware-driven optical fractionator. For the vSub and ventral DG, a 
2-way ANOVA was used to determine main effects and interac-
tion of MAM and peripubertal diazepam administration; 1-way 
ANOVA followed by Bonferroni posthoc tests were used to deter-
mine difference among groups. For the BLA, difference between 
Sal and MAM rats was determined by Student’s t test. All statisti-
cal tests were performed using SPSS (IBM Software). Data were 
represented as mean ± SEM.
Results
Loss of parvalbumin interneurons in vSub and DG of the hip-
pocampus of MAM rats was attenuated by peripubertal admin-
istration of diazepam
The average section thickness for all animals was 20.0 ± 0.04 
μm, accounting for a shrinkage of 67% ± 1%, with no signifi-
cant difference among all groups. Parvalbumin interneurons 
of various sizes were observed, similar with previous findings 
(Kemppainen and Pitkänen, 2000). In the vSub, an average of 
5072 ± 319 parvalbumin interneurons was counted in control 
animals (Sal:Veh, n = 4) Two-way ANOVA revealed a significant 
effect of MAM (F1,13 = 103.376, P < .001) and a significant interac-
tion of MAM and diazepam treatment (F1,13 = 9.017, P = .01). Given 
this significant interaction, 1-way ANOVA was used to determine 
differences among groups. Peripubertal administration of diaz-
epam did not significantly influence the number of parvalbumin 
interneurons in Sal animals (Sal:DZ, 4733 ± 210, n = 4). However, 
in MAM:Veh rats, the number of parvalbumin interneurons was 
significantly less (n = 5, 2375 ± 109, 1-way ANOVA, F3,13 = 40.092, P < . 
001; Bonferroni posthoc test, MAM:Veh vs Sal:Veh, P < . 001). MAM 
rats with peripubertal administration of diazepam had signifi-
cantly more parvalbumin interneurons compared with MAM:Veh 
(MAM:DZ, n = 4, 3355 ± 173, P = .047, Bonferroni posthoc test); how-
ever, this number was still significantly lower compared with Sal 
rats (MAM:DZ vs Sal:Veh, P < . 001) (Figure 1c).
For comparison, parvalbumin interneurons in the hilus of the 
ventral DG were also counted. Two-way ANOVA revealed a signif-
icant interaction (F1,12 = 27.97, P = .0002) and a significant effect of 
MAM (F1,12 = 9.934, P = .0083, n = 4 for all groups). Consistent with 
previous studies (Gill and Grace, 2014), MAM:Veh rats exhibited 
significantly fewer parvalbumin interneurons (824 ± 54) than 
Sal:Veh rats (1417 ± 87). MAM rats with peripubertal diazepam 
showed significantly more parvalbumin interneurons than 
MAM:Veh (MAM:DZ, 1211 ± 76, P = .01, Bonferroni posthoc follow-
ing 1-way ANOVA), which was not significantly different from 
Sal:Veh and Sal:DZ rats (1060 ± 59) (Figure 1d).
MAM Rats Did Not Exhibit Loss of Parvalbumin 
Interneurons in the BLA
Shrinkage of sections throughout BLA of all animals was 64% 
± 1%, rendering an average thickness of sections after shrink-
age of 20.2 ± 0.6 μm. The number of parvalbumin interneurons 
averaged 3283 ± 175 in Sal rats (n = 5), which was similar to that 
reported previously (Rostkowski et al., 2009). We did not observe 
Figure 1. The loss of parvalbumin interneurons in methylazoxymethanol acetate (MAM) rats was attenuated by peripubertal diazepam administration. (a) Images of 
ventral subiculum (vSub) from saline (Sal), MAM, and MAM: diazepam (DZ) animals; scale bar = 100 μm. Boundaries of the counting area, pyramidal cell layer of vSub, 
are delineated by dotted lines. (b) Example image of parvalbumin interneurons. Arrows point to parvalbumin cells in focus; scale bar = 10 μm. (c) MAM rats exhibited 
a significantly lower number of parvalbumin interneurons in the vSub; however, MAM rats with peripubertal administration of diazepam (MAM:DZ) showed a signifi-
cantly higher number of parvalbumin interneurons in the vSub compared with MAM:Veh rats, although the number is still significantly lower compared with Sal:Veh 
and Sal:DZ rats. *P < . 05; ***P < . 001. (d) In the hilus of the ventral DG, MAM:Veh rats showed a significantly lower number of parvalbmin interneurons than Sal:Veh, which 
was significantly attenuated in the MAM:DZ rats. Sal:DZ rats showed a significantly lower PV number than Sal:Veh rats. (e) The number of parvalbumin interneurons 
in the basolateral amygdala (BLA) did not differ significantly between Sal and MAM rats.
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significant differences between Sal and MAM rats in the number 
of parvalbumin neurons (MAM, 3797 ± 372, n = 5, t8 = -1.247, P > .05, 
Student t test) (Figure 1e).
Discussion
Using an unbiased stereological method, we observed a decrease 
in the number of parvalbumin positive interneurons in the vSub 
and ventral DG of the hippocampus of rats with the MAM devel-
opmental disruption model of schizophrenia, consistent with 
previous findings (Penschuck et al., 2006; Lodge et al., 2009; Chen 
et al., 2014; Gill and Grace, 2014). The decrease in parvalbumin 
immunostaining in the vSub and ventral DG is consistent with 
our previous studies (Lodge et al., 2009; Gill and Grace, 2014). 
Indeed, MAM-E17 treatment exerts a greater impact on parval-
bumin interneurons in the ventral hippocampus. The hilus of 
the ventral DG was reported to show a reduced level of parval-
bumin expression paralleled by a reduced number of parvalbu-
min cells; in contrast, a reduced parvalbumin expression was 
not accompanied by loss of parvalbumin cells in the dorsal hip-
pocampus (Gill and Grace, 2014). Although we have not ruled 
out the possibility that our data reflect a loss of PV protein levels 
rather than a loss of PV neurons in the vSub, the large decrease 
in parvalbumin immunostaining highly suggests loss of parval-
bumin interneurons in this region. Although peripubertal diaz-
epam significantly increased parvalbumin interneurons in MAM 
rats in both vSub and ventral DG, the magnitude of the impact 
was different. MAM rats with peripubertal diazepam exhibited 
significantly lower number of parvalbumin interneurons in the 
vSub than controls; however, in the ventral DG, the number is 
not significantly different from controls. It is not clear why there 
was a small but significant (P = .02) decrease in the number of 
parvalbumin interneurons in the Sal:DZ rats compared with 
Sal:Veh, Nonetheless, peripubertal diazepam effectively attenu-
ated loss of parvalbumin interneurons in both regions of the 
ventral hippocampus of MAM rats.
In contrast to the marked reduction of parvalbumin 
interneuron population in the ventral hippocampus of MAM 
rats, we did not observe any significant difference in the number 
of parvalbumin interneurons in the BLA. The specific impact of 
MAM-E17 on the hippocampus could be due to different prena-
tal development trajectories of the hippocampus and BLA. The 
peak of cell proliferation in the hippocampus is around E16 to 
E18 (Bayer, 1980), but BLA is actively developing between E14 and 
E16 (Berdel et  al., 1997). As a mitotoxin, the effect of MAM in 
disrupting cell division lasts 12 to 24 hours after injection, when 
the hippocampus is actively developing but the BLA has already 
undergone development. Moreover, whether parvalbumin 
interneurons in the BLA of schizophrenia patients are altered 
is still unclear. Some early findings had suggested reduced 
GABAergic signaling in the BLA, but no recent work has focused 
on the GABAergic system in the BLA (Benes, 2010). Reduction in 
parvalbumin expression in the BLA has been observed in some 
animal models of schizophrenia (Romon et al., 2011; Nakamura 
et al., 2015) but not others (Pollard et al., 2012).
Parvalbumin interneurons, especially those in the hip-
pocampus, are sensitive to stress. Hippocampal parvalbumin 
neurons were reduced in both social defeat and chronic mild 
stress models (Czeh et al, 2015; Hu et al, 2010). A hyperrespon-
sivity to stress was observed in MAM rats during the peripu-
bertal period; for example, enhanced baseline level of anxiety, 
increased vocalization to footshock, and lack of accommoda-
tion of the corticosterone response to chronic stress (Du and 
Grace, 2013; Zimmerman et  al., 2013). This hyperresponsivity 
to stress might cause these rats to exhibit stress responses 
to normal housing conditions, which could damage parvalbu-
min interneurons in the hippocampus secondary to amygdala 
activation. The density of parvalbumin interneurons is already 
lower in MAM rats at PD25 (Gill and Grace, 2014), which could 
explain the incomplete reversal of the reduced parvalbumin 
interneuron numbers in MAM rats with peripubertal admin-
istration of diazepam on PD 31 to 40. However, by alleviating 
the hyperresponsivity to stress, this treatment prevents further 
loss of parvalbumin interneurons. Furthermore, as reported 
in previous studies, peripubertal administration of diazepam 
decreased the hyperdopaminergic state and the heightened 
anxiety levels in MAM rats (Du and Grace, 2013, 2016), which 
is probably contributed by the attenuated loss of parvalbumin 
interneurons. Nonetheless, this treatment has some efficacy to 
protect parvalbumin interneurons and by doing so, appears to 
keep the system beneath a threshold level of activation such 
that the cascade of events that is proposed to lead to the emer-
gence of hyperdopaminergic state in MAM rats will not be 
triggered. Other treatments early in life, such as antipsychot-
ics (Piontkewitz et al., 2012) or antioxidants (Cabungcal et al., 
2014), have also been shown to effectively protect parvalbumin 
interneurons and prevent other schizophrenia-like symptoms 
from emerging in developmental disruption models of schizo-
phrenia. Therefore, we propose that controlling the hyperre-
sponsivity to stress during the premorbid period in subjects at 
risk of schizophrenia, either pharmacologically or nonpharma-
cologically, may be an effective mean to prevent development 
of schizophrenia later in life.
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